U.S. markets closed

Nuwellis, Inc. (NUWE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5393-0.0744 (-12.12%)
At close: 04:00PM EDT
0.5698 +0.03 (+5.66%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.6137
Bid0.5410 x 900
Ask0.5591 x 800
Day's Range0.5393 - 0.6200
52 Week Range0.4700 - 2.4800
Avg. Volume3,501,126
Market Cap5.683M
Beta (5Y Monthly)0.22
PE Ratio (TTM)N/A
EPS (TTM)-2.1750
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NUWE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Nuwellis, Inc.
    Analyst Report: Thermo Fisher Scientific Inc.Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2022 (revenue figures include some cross-segment revenue): analytical technologies (15% of sales); specialty diagnostic products (10%); life science solutions (30%); and lab products and services, which includes CRO services (51%).
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • GlobeNewswire

    Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

    REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overloadMINNEAPOLIS, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the activation of three additional sites for its pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study. Jefferson Abington Hospital in Pen

  • GlobeNewswire

    Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

    Data show ultrafiltration for post-operative CABG patients provides a safe and effective method for managing fluid balance and reducing mortality ratesMINNEAPOLIS, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the publication of key clinical data supporting the use of ultrafiltration with the Aquadex FlexFlow® System in high-risk postoperative coronary artery bypass graf

  • GlobeNewswire

    U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology

    Enabling improved fluid balance and safety when performing dialysis and hemofiltration in pediatrics and neonatesMINNEAPOLIS, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a commercial stage company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it was awarded a patent from the United States Patent and Trademark Office for a novel innovation that provides for improved fluid balance and safety in pediatric dialysis and hemofil